Pure Pharmacy (Front Door Pharmacy, LLC), Houston, TX

Is Pure Pharmacy (Front Door Pharmacy, LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Pure Pharmacy (Front Door Pharmacy, LLC) hold a Texas pharmacy license?

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed.

Has Pure Pharmacy (Front Door Pharmacy, LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jul 1, 2020) for Pure Pharmacy (Front Door Pharmacy, LLC). Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Front Door Pharmacy, LLC; Pure Pharmacy
Location
Houston, TX
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
1
Latest action on that page
Jun 7, 2021
FDA Data Dashboard inspections
2 inspections: 2 OAI; 3 published Form 483s
Form 483 text on this page
1 Form 483, 7 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Front Door Pharmacy, LLC, (dba Pure Pharmacy), a 503A facility, with 3 dated actions.

Document
Jun 7, 2021Form 483483 Issued 06/07/2021FDA copy (archived)
Jul 1, 2020Warning letterWarning Letter (07/01/2020)FDA copy (archived)
Mar 18, 2019Form 483483 Issued 03/18/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Front Door Pharmacy, LLC, Houston, TX (FEI number 3012937475), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 7, 2021Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30129374751143371
Mar 18, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30129374751083007

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 7 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 11, 2021 to Jun 7, 2021: 7 observations

Firm on the cover
Front Door Pharmacy, LLC dba PurePharmacy (Pure Pharmaceuticals), 8973 Interchange Dr, Houston, TX 77054-2513
FEI number
3012937475
Establishment type on the cover
Sterile Drug Producer
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Personnel were observed conducting aseptic manipulations or placing equipment/supplies in an area that blocked the movement of first pass air around an open unit, whether before or after it is filled with sterile product.

Specifically, during the visual sterile production observation of the finished sterile drug product, P105 (PAP30MG/ PHE1MG/ PGE10MCG), Lot # 051321@I <Redacted B4> Expiry 7/16/21 being performed by the pharmacy PIC, the following conditions were observed:

A. Reaching over filled sterile <Redacted B4> unstopped vials to fill empty vials.

B. Placed a tray of empty vials awaiting filling in between the HEPA filter and the vials undergoing <Redacted B4> filling, resulting in an interruption of 1st air for the vials being processed the ISO 5 LAFU.

Observation 2

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that prove a challenge to aseptic operations.

Specifically, your pharmacy fail to provide an adequate justification for your facility's media fill program in order to simulate aseptic production operations for the worst-case activities and conditions. For example, your firm’s media fill program documented within procedure, Conduct High Risk Media Fill Test, PURE_SOP 3.9.6 Conduct High Risk Media Fill Test fail to represent actual aseptic production practices, which include the stopper placement and affixing the <Redacted B4> to the vial. Repeat Observation

Observation 3

Environmental monitoring was not performed in your aseptic processing areas.

Specifically, environmental Monitoring and measurement frequency of microbiological contamination (viable/non-viable monitoring) of the air in the ISO 5 zone is inadequate. Your pharmacy fail to establish a viable monitoring program during sterile drug production within the ISO 5 LAFU. Additionally, during a review of your pharmacy's cleanroom re-certification for VIABLE Report 1.27.2021, which documents the <Redacted B4> assessment of air, and Surface contaminates within ISO 7 and ISO 8 Ante-room, fail to include the ISO 5 LAFU.

Observation 4

The use of sporicidal agents in the cleanrooms and ISO 5 classified aseptic processing area was inadequate.

Specifically, your firm failed to validate the sporicidal agent, <Redacted B4> Sporicidal Disinfectant Cleaner for its intended use within the cleanroom and aseptic production processing area. Repeat Observation

Observation 5

Your facility design allowed the influx of poor-quality air into a higher classified area.

Specifically, your firm air returns are adjacent to your HEPA filters in the ceiling of the ISO 8 Anteroom and ISO 7 Cleanroom <Redacted B4> used in the production of sterile drugs. Your pharmacy fail to provide records and/or documents (smoke study) in support of adequate air circulation in the prevention of an influx of poor quality air into a higher classified area. Repeat Observation

Observation 6

You produced hazardous drugs without providing adequate segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically, your pharmacy produces the non-sterile hazardous drug, Testosterone Cream 100 mg/mL and Estradiol 0.1MG/GM Cream without adequate segregation, deactivation, and adequate cleaning program to prevent cross-contamination. All non-sterile compounded drugs are compounded in the same designated drug production area without adequate cleaning requirements. Your firm's hazardous material SOP, Hazardous Material_4.9.6, Handling Hazardous Material - Pharmacy procedure failed to include cleaning requirements to deactivate hazardous drug products and components. Your pharmacy technician report you firm uses dish detergent to wash and allow to <Redacted B4>. Equipment is wiped using <Redacted 4> Repeat Observation

Observation 7

ISO-5 classified areas were not certified under dynamic conditions.

Specifically, unidirectional airflow was not verified under operational conditions. Your firm’s clean room re-certification reports tests dated 1/27/2021, 8/5/2020, 2/12/2020, and 8/15/2019 were documented as being performed in dynamic conditions. On 5/24/2021, PIC reported no aseptic production simulation was performed at the time of any of the documented cleanroom and ISO 5 aseptic production processing areas during re-certifications. Repeat Observation

Linked 483s whose text is not shown

State board of pharmacy records

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.